ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer

Core Insights - ProPhase Labs Inc. has successfully completed a validation study for its BE-Smart molecular diagnostic test, achieving a technical success rate of over 95% in detecting biomarkers related to esophageal diseases [2][3] - The BE-Smart test is designed to work with both brush and forceps biopsies, positioning it uniquely in the market and targeting a potential market size of approximately $10 billion [4] - The increasing adoption of brush biopsies in clinical practice is driven by their improved diagnostic yield and safety profile, addressing limitations of traditional forceps biopsies [5][6] Company Overview - ProPhase Labs Inc. is a next-generation biotech and genomics company focused on innovative healthcare solutions, including diagnostic tests for early detection of esophageal cancer [8] - The company aims to revolutionize healthcare through bold innovation and actionable insights, with a commitment to executional excellence and smart diversification [9] Industry Context - Esophageal adenocarcinoma (EAC) has seen a dramatic increase in incidence, with a 750% rise since the 1970s and a 5-year mortality rate exceeding 79%, highlighting the urgent need for effective diagnostic tools [3] - The shift towards brush biopsies is gaining traction in both the U.S. and internationally, with expanded payer coverage now reaching over 73 million lives, indicating a growing recognition of their benefits [6][7]